Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 35404441)

  • 1. The Spatial Landscape of Progression and Immunoediting in Primary Melanoma at Single-Cell Resolution.
    Nirmal AJ; Maliga Z; Vallius T; Quattrochi B; Chen AA; Jacobson CA; Pelletier RJ; Yapp C; Arias-Camison R; Chen YA; Lian CG; Murphy GF; Santagata S; Sorger PK
    Cancer Discov; 2022 Jun; 12(6):1518-1541. PubMed ID: 35404441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional profiling of macrophages in situ in metastatic melanoma reveals localization-dependent phenotypes and function.
    Martinek J; Lin J; Kim KI; Wang VG; Wu TC; Chiorazzi M; Boruchov H; Gulati A; Seeniraj S; Sun L; Marches F; Robson P; Rongvaux A; Flavell RA; George J; Chuang JH; Banchereau J; Palucka K
    Cell Rep Med; 2022 May; 3(5):100621. PubMed ID: 35584631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spatially Resolved Transcriptomics Enables Dissection of Genetic Heterogeneity in Stage III Cutaneous Malignant Melanoma.
    Thrane K; Eriksson H; Maaskola J; Hansson J; Lundeberg J
    Cancer Res; 2018 Oct; 78(20):5970-5979. PubMed ID: 30154148
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stromal reaction in cutaneous melanoma.
    Labrousse AL; Ntayi C; Hornebeck W; Bernard P
    Crit Rev Oncol Hematol; 2004 Mar; 49(3):269-75. PubMed ID: 15036266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons from cancer immunoediting in cutaneous melanoma.
    Aris M; Barrio MM; Mordoh J
    Clin Dev Immunol; 2012; 2012():192719. PubMed ID: 22924051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor CD155 Expression Is Associated with Resistance to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Lepletier A; Madore J; O'Donnell JS; Johnston RL; Li XY; McDonald E; Ahern E; Kuchel A; Eastgate M; Pearson SA; Mallardo D; Ascierto PA; Massi D; Merelli B; Mandala M; Wilmott JS; Menzies AM; Leduc C; Stagg J; Routy B; Long GV; Scolyer RA; Bald T; Waddell N; Dougall WC; Teng MWL; Smyth MJ
    Clin Cancer Res; 2020 Jul; 26(14):3671-3681. PubMed ID: 32345648
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplexed 3D atlas of state transitions and immune interaction in colorectal cancer.
    Lin JR; Wang S; Coy S; Chen YA; Yapp C; Tyler M; Nariya MK; Heiser CN; Lau KS; Santagata S; Sorger PK
    Cell; 2023 Jan; 186(2):363-381.e19. PubMed ID: 36669472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune System Evasion as Hallmark of Melanoma Progression: The Role of Dendritic Cells.
    Tucci M; Passarelli A; Mannavola F; Felici C; Stucci LS; Cives M; Silvestris F
    Front Oncol; 2019; 9():1148. PubMed ID: 31750245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary cilium depletion typifies cutaneous melanoma in situ and malignant melanoma.
    Kim J; Dabiri S; Seeley ES
    PLoS One; 2011; 6(11):e27410. PubMed ID: 22096570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. OMIC signatures to understand cancer immunosurveillance and immunoediting: Melanoma and immune cells interplay in immunotherapy.
    León-Letelier RA; Bonifaz LC; Fuentes-Pananá EM
    J Leukoc Biol; 2019 May; 105(5):915-933. PubMed ID: 30698862
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of cyclo-oxygenase-2 in macrophages associated with cutaneous melanoma at different stages of progression.
    Bianchini F; Massi D; Marconi C; Franchi A; Baroni G; Santucci M; Mannini A; Mugnai G; Calorini L
    Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):320-8. PubMed ID: 17499752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. USP18 is crucial for IFN-γ-mediated inhibition of B16 melanoma tumorigenesis and antitumor immunity.
    Hong B; Li H; Lu Y; Zhang M; Zheng Y; Qian J; Yi Q
    Mol Cancer; 2014 May; 13():132. PubMed ID: 24884733
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microsatellite Instability Predicts Response to Anti-PD1 Immunotherapy in Metastatic Melanoma.
    Roncati L
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):341-343. PubMed ID: 30665488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paracrine Activin-A Signaling Promotes Melanoma Growth and Metastasis through Immune Evasion.
    Donovan P; Dubey OA; Kallioinen S; Rogers KW; Muehlethaler K; Müller P; Rimoldi D; Constam DB
    J Invest Dermatol; 2017 Dec; 137(12):2578-2587. PubMed ID: 28844941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel immune signatures associated with dysplastic naevi and primary cutaneous melanoma in human skin.
    Yan BY; Garcet S; Gulati N; Kiecker F; Fuentes-Duculan J; Gilleaudeau P; Sullivan-Whalen M; Shemer A; Mitsui H; Krueger JG
    Exp Dermatol; 2019 Jan; 28(1):35-44. PubMed ID: 30326165
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome.
    Vescovi R; Monti M; Moratto D; Paolini L; Consoli F; Benerini L; Melocchi L; Calza S; Chiudinelli M; Rossi G; Bugatti M; Maio M; Fonsatti E; Farisoglio C; Simbolo M; Almici C; Verardi R; Scarpa A; Bergese P; Manganoni A; Facchetti F; Vermi W
    Cancer Immunol Res; 2019 Jan; 7(1):12-28. PubMed ID: 30401679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor infiltrating lymphocytes: The regulator of melanoma evolution.
    Antohe M; Nedelcu RI; Nichita L; Popp CG; Cioplea M; Brinzea A; Hodorogea A; Calinescu A; Balaban M; Ion DA; Diaconu C; Bleotu C; Pirici D; Zurac SA; Turcu G
    Oncol Lett; 2019 May; 17(5):4155-4161. PubMed ID: 30944610
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of MIF-CD74 Signalling on Macrophages and Dendritic Cells Restores the Antitumour Immune Response Against Metastatic Melanoma.
    Figueiredo CR; Azevedo RA; Mousdell S; Resende-Lara PT; Ireland L; Santos A; Girola N; Cunha RLOR; Schmid MC; Polonelli L; Travassos LR; Mielgo A
    Front Immunol; 2018; 9():1132. PubMed ID: 29875777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune response against human primary malignant melanoma: a distinct cytokine mRNA profile associated with spontaneous regression.
    Wagner SN; Schultewolter T; Wagner C; Briedigkeit L; Becker JC; Kwasnicka HM; Goos M
    Lab Invest; 1998 May; 78(5):541-50. PubMed ID: 9605179
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy.
    Basher F; Dhar P; Wang X; Wainwright DA; Zhang B; Sosman J; Ji Z; Wu JD
    J Hematol Oncol; 2020 Jun; 13(1):74. PubMed ID: 32517713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.